Zobrazeno 1 - 10
of 5 613
pro vyhledávání: '"PALBOCICLIB"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Acute kidney injury (AKI) is a common clinical problem, and patients who survive AKI have a high risk of chronic kidney disease (CKD). The acute protective effects of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in AKI have been exami
Externí odkaz:
https://doaj.org/article/57de70f7347b4015a8791234feab1dbf
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Autor:
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5722-5729 (2024)
Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact
Externí odkaz:
https://doaj.org/article/a433ba64f8604e4fafa1869340c79037
Autor:
Takayuki Kobayashi, Meiko Nishimura, Mari Hosonaga, Rika Kizawa, Saori Kawai, Yosuke Aoyama, Yukinori Ozaki, Ippei Fukada, Fumikata Hara, Toshimi Takano, Takayuki Ueno
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Absolute lymphocyte count (ALC) is a predictive and prognostic factor for various tumor types, including breast cancer. Palbociclib is a CDK4/6 inhibitor widely used for the treatment of metastatic estrogen receptor (ER)-positive,
Externí odkaz:
https://doaj.org/article/1e6f7c53792d4145b42f0e111048dcb5
Autor:
Rand K. Jadallah, Ahmed H. Al Sharie, Saja M. Alzghoul, Jawad M. Al-Karaki, Mohammad S. Bani Amer, Tariq H. Rawashdeh, Osama Alshari
Publikováno v:
Radiology Case Reports, Vol 19, Iss 9, Pp 4049-4054 (2024)
The management of advanced metastasized breast cancer (BC) is a clinically challenging entity with a wide spectrum of novel therapeutics being introduced to the market. Such agents have remodeled BC treatment landscape and prolonged patients’ survi
Externí odkaz:
https://doaj.org/article/d6dc1c8484a142c78d3ebc441ef26a5b
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 395-418 (2024)
Abstract Introduction Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain
Externí odkaz:
https://doaj.org/article/d3d5c5d38dd54e5fb401805a467c3fba
Autor:
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhib
Externí odkaz:
https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68
Autor:
Arantza Lamas-Paz, Alejandro Hionides-Gutiérrez, Feifei Guo, Gonzalo Jorquera, Laura Morán-Blanco, Raquel Benedé-Ubieto, Mariana Mesquita, Olga Estévez-Vázquez, Kang Zheng, Marina Mazariegos, Elena Vázquez-Ogando, Elena Blázquez-López, Iris Asensio, Beste Mutlu, Beatriz Gomez-Santos, María Isabel Peligros, Javier Vaquero, Rafael Bañares, Teresa C. Delgado, María Luz Martínez-Chantar, Eduardo Martínez-Naves, Carlos Sanz-García, Mohamed Ramadan Mohamed, Sofía Tesolato, Pilar Iniesta, Rocío Gallego-Durán, Douglas Maya-Miles, Javier Ampuero, Manuel Romero-Gómez, Ana Martínez-Alcocer, David Sanfeliu-Redondo, Anabel Fernández-Iglesias, Jordi Gracia-Sancho, Mar Coll, Isabel Graupera, Pere Ginès, Andrea Ciudin, Jesús Rivera-Esteban, Juan M. Pericàs, Matías A. Ávila, Maria Dolores Frutos, Carlos Manuel Martínez-Cáceres, Bruno Ramos-Molina, Patricia Aspichueta, Pere Puigserver, Yulia A. Nevzorova, Francisco Javier Cubero
Publikováno v:
JHEP Reports, Vol 7, Iss 1, Pp 101230- (2025)
Background & Aims: Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of
Externí odkaz:
https://doaj.org/article/4e2f28ede80d4cfa8f3201c467cc1073
Autor:
Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Sławomir Blamek, Daria Handkiewicz-Junak, Michał Jarząb
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However,
Externí odkaz:
https://doaj.org/article/9d9e1f7a93a64468bcf194119069923b
Autor:
Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop
Publikováno v:
Breast, Vol 78, Iss , Pp 103815- (2024)
Background: This paper aimed to evaluate the effectiveness of incorporating CDK 4/6 inhibitors (CDK4/6i) into ET for the adjuvant treatment of HR + HER2-resected early-stage breast cancer (ESBC) patients, employing meta-analysis. Methods: In this pap
Externí odkaz:
https://doaj.org/article/330e286730524e79849f3b4010a9a9bd